Evidence map›Paper›PMID 37896924›Full record

ArticleVaccines2023

Generation of a DSF-Guided Refolded Bacterially Expressed Hemagglutinin Ectodomain of Influenza Virus A/Puerto Rico/8/1934 H1N1 as a Model for Influenza Vaccine Antigens.

Vlad-Constantin Tofan, Andreea-Laura Ermeneanu, Iuliana Caraș, Alina Lenghel, Irina-Elena Ionescu, Cătălin Țucureanu, Claudiu Gal, Crina-Georgeta Stăvaru, Adrian Onu

Abstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vlad-Constantin Tofan"Cantacuzino" Institute, 050096 Bucharest, Romania.ORCID 0000-0003-4052-2383
Andreea-Laura Ermeneanu"Cantacuzino" Institute, 050096 Bucharest, Romania.
Iuliana Caraș"Cantacuzino" Institute, 050096 Bucharest, Romania.
Alina Lenghel"Cantacuzino" Institute, 050096 Bucharest, Romania.
Irina-Elena Ionescu"Cantacuzino" Institute, 050096 Bucharest, Romania.
Cătălin Țucureanu"Cantacuzino" Institute, 050096 Bucharest, Romania.ORCID 0000-0001-5775-5939
Claudiu Gal"Cantacuzino" Institute, 050096 Bucharest, Romania.ORCID 0000-0003-0000-9737
Crina-Georgeta Stăvaru"Cantacuzino" Institute, 050096 Bucharest, Romania.
Adrian Onu"Cantacuzino" Institute, 050096 Bucharest, Romania.ORCID 0000-0001-8724-9754

Funding

Ministerul Cercetării și Inovării 25N/2023, project PN 23 44 01 01Ministerul Cercetării și Inovării PN-III-P1-1.2-PCCDI-2017-0529 / 62PCCDI ⁄ 2018
6 · The paper itself

Abstract

Influenza virus infections represent an ongoing public health threat as well as an economic burden. Although seasonal influenza vaccines have been available for some decades, efforts are being made to generate new efficient, flexible, and cost-effective technologies to be transferred into production. Our work describes the development of a model influenza hemagglutinin antigen that is capable of inducing protection against viral challenge in mice. High amounts of the H1 hemagglutinin ectodomain, HA

Indexed as

differential scanning fluorimetryhemagglutinininfluenzarecombinant protein expressionvaccine

Identifiers

PMID37896924
PMCPMC10610769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.